Figure 3 | Scientific Reports

Figure 3

From: Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis

Figure 3

Subcutaneous TAF injection in C57BL/6 J mice results in different pharmacokinetics across the three key analytes. The data are shown as linear (A–C) and semilog (D–F) plots and all concentration units are represented in nanomolar (nM) for ease of comparison. Concentration–time profiles of plasma TAF (A and D; red circles), plasma TFV (B and E; blue circles), and PMBC TFV-DP (C and F; green circles) are shown as means ± SD (N = 4 per group). The assay LLOQs are: TAF, 0.06 nM (0.03 ng mL-1); TFV, 3.5 nM (1 ng mL-1); TFV-DP, 5 nM (based on 5 fmol/sample, and a median of 5.0 × 106 PBMCs per sample).

Back to article page